Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study
Cancer Medicine · 2023
DOI: 10.1002/cam4.6232 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Ya Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Sci…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Commission of Shanghai Municipality.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
Acquired resistance represents a bottleneck to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung cancer. Our study aimed to explore the efficacy of antiangiogenic‐based therapy in osimertinib‐resistant NSCLC patients and assess the efficacy of anlotinib in vitro study.
Methods
Our multicenter study retrospectively collected 268 osimertinib‐resistant NSCLC patients with EGFR T790M mutation and explored the efficacy of anlotinib in patients and in vitro.
Results
PFS was significantly longer in the antiangiogenic‐based therapy group than in the immunotherapy group (HR: 0.71, p = 0.050) and the chemotherapy group (HR: 0.28, p = 0.001). Both the ORR and DCR of the antiangiogenic‐based group were higher than the immunotherapy group and the chemotherapy group. Subgroup analysis showed a trend of more benefits from the anlotinib‐based therapy than the bevacizumab‐based therapy in terms of PFS (HR: 0.63, p = 0.087) and OS (HR: 0.52, p = 0.063). In vitro assays verified that anlotinib alone or combined with osimertinib exerted potent cytotoxicity to T790M‐mutant H1975 cell line with acquired osimertinib resistance.
Conclusions
Our study suggested that antiangiogenic‐based therapy might improve PFS and OS in EGFR‐mutant NSCLC patients with acquired resistance to osimertinib. Moreover, anlotinib‐based therapy could be a promising effective treatment for this group of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
- Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Oncology, The Affiliated Hospital of QingDao University, QingDao, China.
- Department of Respiratory and Clinical Care Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
ORCID-Profile: Ya Chen, Baohui Han
Förderung
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Chen, Y., Liu, H., Hu, N., Wang, Y., Yang, Z., Zhang, J., & Han, B. (2023). Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study. Cancer Medicine. https://doi.org/10.1002/cam4.6232
Vancouver
Chen Y, Liu H, Hu N, Wang Y, Yang Z, Zhang J, et al. Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study. Cancer Medicine. 2023. doi:10.1002/cam4.6232
BibTeX
@article{Chen2023,
author = {Chen, Ya and Liu, Hongyu and Hu, Nana and Wang, Yanan and Yang, Zhengyu and Zhang, Junqiang and Han, Baohui},
title = {Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6232}
}
EUVIMED